The purpose of this guidance is to clarify circumstances under which the FDA’s Center for Drug Evaluation and Research (CDER) may refuse to file a new drug application (NDA) or supplemental NDA (21 CFR 314.101(d)) or a biologics license application (BLA) or supplemental BLA (21 CFR 601.2) for a therapeutic biological product regulated by CDER,2 and to underscore the importance of submitting a complete application to minimize the chance of a refuse-to-file (RTF) action by the FDA. In particular, this guidance focuses on the FDA’s policy for refusing to file an NDA under § 314.101(d)(3) when the NDA is incomplete because it does not on its face contain information required under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and 21 CFR 314.50
Artigos recentes
- COMMISSION IMPLEMENTING DECISION (EU) 2022/6 of 4 January 2022 amending Implementing Decision (EU) 2021/1182
- Publicado Regulamento (UE) 2021/2282 do Parlamento Europeu e do Conselho relativo à avaliação das tecnologias da saúde
- Progressive roll-out of the In Vitro Diagnostic Medical Devices Regulation
- International regulators’ reflections on remote approaches to GCP and GMP regulatory oversight during COVID-19 pandemic
- EMA launches the Regulatory Science Research Needs initiative
- FDA final guidance on CMC postapproval changes for annual reports
- PESSOA RESPONSÁVEL de DISPOSITIVOS MÉDICOS : Uma formação muito esclarecedora e útil com uma excelente formadora
- Considerations for the Use of Real-World Data and RealWorld Evidence to Support Regulatory Decision-Making for Drug and Biological Products